colistimethate sodium


Universal Medical Industry


Universal Medical Industry
Concise Prescribing Info
Colistimethate Na (equiv to colistin)
Severe gram -ve infections especially those due to P. aeruginosa & in multidrug-resistant Pseudomonas or Acinetobacter CNS infections.
Dosage/Direction for Use
Adult & childn IV/IM 2.5-5 mg/kg daily in 2-4 divided doses, depending on the severity of the infection. Max: 5 mg/kg. Oral inhalation 33.33-66.66 mg (1-2 million IU) bid-tid. Renal impairment serum creatinine 2.6-4 mg/100 mL 1.5 mg/kg daily every 36 hr, 1.6-2.5 mg/100 mL 2.5 mg/kg daily in a single dose or in 2 divided doses, 1.3-1.5 mg/100 mL 2.5-3.8 mg/kg daily in 2 divided doses.
Hypersensitivity. Myasthenia gravis.
Special Precautions
May affect ability to drive or operate machinery. Monitor plasma conc during treatment in patients w/ renal impairment & cystic fibrosis, & w/ neonates. Acute attacks of porphyria. Pregnancy (2nd & 3rd trimesters) & lactation.
Adverse Reactions
Dizziness, confusion & visual disturbances. Pain & local irritation. Neurotoxicity (apnoea, perioral & peripheral paraesthesia, vertigo); nephrotoxicity, hypersensitivity reactions including rash; inj site reactions.
Drug Interactions
Additive effects of neurotoxic, ototoxic & nephrotoxic w/ cephalosphorin group, vancomycin, capreomycin, minocycline, amphotericin B, bacitracin, cisplatin, methoxyflurane, polymyxin B. Prolonged duration of neuromuscular blockers.
MIMS Class
ATC Classification
J01XB01 - colistin ; Belongs to the class of polymyxins. Used in the systemic treatment of infections.
Colistin-150 inj 150 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in